Most Recent
Westpac will pay $35 million to settle a case brought by ASIC alleging the bank breached responsible lending laws through its automated home loan system, the largest civil penalty ever awarded under the National Credit Act.
A trial set to begin Monday morning in ASIC's landmark case against Westpac alleging the bank breached responsible lending laws was postponed amid settlement talks, which were expected to continue into the evening.
A judge on Friday bemoaned the slow progress of an unfair dismissal suit brought against the CFMMEU by two whistleblowers, telling lawyers at a hearing Friday he wanted "something to happen" in the case
Generic drug maker Alphapharm is fighting a bid by global pharmaceutical giant Sanofi-Aventis to block the listing of one of its injector pens, saying the proposed injunction should be denied because Sanofi is seeking to amend the patent at issue.
A judge has denied a bid for a strict regime for dealing with confidential information in a lawsuit between cheese giants Fonterra and Bega over alleged violations of the terms of a trade mark licensing agreement.
A Federal Court judge has criticised Volkswagen for being "uncooperative" in refusing to tell the court who authorised the defeat device at the heart of the auto giant's diesel emissions cheating scandal.
Six major car companies indicated Tuesday they were open to a quick settlement of class actions brought on behalf of potentially hundreds of thousands of Australian drivers whose cars were fitted with defective and deadly Takata airbags.
A judge has ruled in-house counsel at Glencore can't view "highly confidential" documents related to the possible sale by Cargill of its Joe White malt business.
The Commonwealth Bank of Australia is seeking to strike out portions of a shareholder class action over allegedly lax anti-money laundering and anti-terrorism financing controls it calls a "vague penumbra" that leaves the bank in the dark about the case against it.
An urgent injunction sought by US-based Millennium Pharmaceuticals to block generic drug maker Dr Reddy's Laboratories from launching a cheap version of the breakthrough cancer drug Velcade has been panned as unnecessary.